What is Axsome Therapeutics's market cap?

Axsome Therapeutics (AXSM) has a market capitalization of $12.3B and trades on NASDAQ.

What is Axsome Therapeutics's revenue and profitability?

Axsome Therapeutics generated $708.2M in trailing twelve-month revenue with a net loss of $188.3M, representing a net margin of -26.6%. Gross margin stands at 92.6%, with free cash flow of -$72.0M. These figures are based on the Q1 2026 filing.

Who are Axsome Therapeutics's competitors?

Axsome Therapeutics's key competitors include AbbVie Inc., Eli Lilly and Company, Harmony Biosciences LLC, and others. These companies compete in similar markets and product categories.

Who does Axsome Therapeutics partner with?

Axsome Therapeutics's notable partners include Pfizer Inc., Jazz Pharmaceuticals plc, Atnahs Pharma UK Limited (Pharmanovia), and others.

What subsidiaries does Axsome Therapeutics have?

Axsome Therapeutics's subsidiaries include Baergic Bio, Inc..

Where is Axsome Therapeutics headquartered?

Axsome Therapeutics is headquartered in United States of America and employs approximately 569 people. It has been publicly traded since 2015.

Axsome Therapeutics

AXSM

Axsome Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) disorders.

Market cap

$12.27B+146%

Revenue$708.2M+63.9%

Net income-$188.3M+32.3%

Free cash flow-$72.0M+39.4%

EPS (diluted)-$3.72+35.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$189.4MMiss by $1.5M EPS-$1.26Miss by $0.41

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$220.9M

EPS estimate-$0.89

Financials

Q1 2026

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Free cash flow-$20.8M+52.4%

Valuation & ratios

Valuation

See full

Market cap$12.27B+146%

Enterprise value$12.18B+151%

P/S17.3×+7.3×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Segments

By product

See full

Royalty$4.1M+269%

Royalty And Milestone Revenue$1.8M+63.2%

Milestone Revenue$500.0K—

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Johnson & Johnson$640.91B+60.1%

AbbVie$453.91B+36.3%

Axsome Therapeutics$12.3B+148%

Alkermes$8.8B+104%

Harmony Biosciences Holdings, Inc.$2.1B+1.5%

Vanda Pharmaceuticals$313.9M+13.3%

Minerva Neurosciences$195.9M+1,234%

By revenue growth

Axsome Therapeutics+63.9%

Eli Lilly+47.4%

Harmony Biosciences Holdings, Inc.+20.7%

Alkermes+10.8%

AbbVie+9.5%

Johnson & Johnson+8.1%

By net margin

Eli Lilly34.99%+12.3pp

Johnson & Johnson21.48%-3.5pp

Harmony Biosciences Holdings, Inc.16.2%-4.3pp

AbbVie5.79%-1.5pp

Alkermes3.97%-19.2pp

Axsome Therapeutics-26.59%+37.8pp

Profile

Axsome Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing innovative therapies for central nervous system (CNS) disorders. The company leverages proprietary medicinal chemistry and formulation technologies to address significant gaps in care for psychiatric and neurological conditions. Its value proposition is centered on delivering differentiated products with novel mechanisms of action to transform patient outcomes in underserved therapeutic segments.

Competitive position

Axsome is a commercial-stage biopharmaceutical company with a growing portfolio of approved CNS drugs and a late-stage pipeline utilizing the 505(b)(2) regulatory pathway to reduce development risk.

GeographiesUnited States, Europe, Middle East, North Africa

Customer segmentsHealthcare Providers, Patients, Wholesale Distributors

Business modelResearch and Development, Direct-to-Market Pharmaceutical Sales, Licensing and Royalties

SuppliersContract Manufacturing Organizations (CMOs), Raw Material Suppliers, Clinical Research Organizations (CROs)

CustomersSpecialty Pharmacies, Wholesale Drug Distributors, Hospitals, Retail Pharmacies

CountryUnited States of America

Listed2015

Employees569.0

CEOHerriot Tabuteau

SectorHealthcare

IndustryBiotechnology

Websiteaxsome.com

FilingsSEC EDGAR

Ask your AI about Axsome Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's market cap?: Axsome Therapeutics (AXSM) has a market capitalization of $12.3B and trades on NASDAQ.
What is Axsome Therapeutics's revenue and profitability?: Axsome Therapeutics generated $708.2M in trailing twelve-month revenue with a net loss of $188.3M, representing a net margin of -26.6%. Gross margin stands at 92.6%, with free cash flow of -$72.0M. These figures are based on the Q1 2026 filing.
Who are Axsome Therapeutics's competitors?: Axsome Therapeutics's key competitors include AbbVie Inc., Eli Lilly and Company, Harmony Biosciences LLC, and others. These companies compete in similar markets and product categories.
Who does Axsome Therapeutics partner with?: Axsome Therapeutics's notable partners include Pfizer Inc., Jazz Pharmaceuticals plc, Atnahs Pharma UK Limited (Pharmanovia), and others.
What subsidiaries does Axsome Therapeutics have?: Axsome Therapeutics's subsidiaries include Baergic Bio, Inc..
Where is Axsome Therapeutics headquartered?: Axsome Therapeutics is headquartered in United States of America and employs approximately 569 people. It has been publicly traded since 2015.